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INTRODUCTION 
 
 
Dermal and transdermal delivery 
              The skin covers 1,4,5,9,13a total surface area of approximately 1.8m2 and 
provides the contact between the human skin and its external environment. This large 
and outermost layer of the human body is easily accessible and hence attractive as a 
non-invasive delivery route for selected drug compounds. Dermal and Transdermal 
drug delivery can have many advantages as compared to other routes of drug 
administration. (22) 
                 Figure 1:                   Skin Structure 
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             Dermal drug delivery is the topical application of drugs to the skin in the 
treatment of localized skin diseases. The advantage of dermal drug delivery is that 
high concentration of drugs can be localized at the site of action, reducing the 
systemic drug levels and therefore also reducing the systemic side effects (22). 
Transdermal drug delivery, on the other hand uses the skin as an alternative route for 
the delivery of systemically acting drugs. This drug delivery route for systemic 
therapy can have several advantages as compared to conventional oral drug 
administration. First of all, it circumvents the variables that could influence 
gastrointestinal absorption. Such as pH, food intake and gastrointestinal motility. 
Secondly it circumvents the first pass hepatic metabolism and is therefore suitable for 
drugs with a low bio-availability. Thirdly transdermal drug delivery can give a 
constant, controlled drug input. This would reduce the need for frequent drug intake, 
especially of drugs with a short biological half-life. Furthermore, variations in drug 
plasma levels can be avoided, reducing the side effects in particular of drugs with a 
narrow therapeutic window. Finally, transdermal drug delivery is easy and painless, 
which in turn will increase patient compliance. 
             Despite these advantages of the skin as a site of drug delivery, only less than 
10 drugs are currently available in the market as a transdermal delivery system. These 
transdermal delivery systems contain drugs including fentanyl, nitro-glycerine, 
scopolamine, clonidine, nicotine, estradiol, and testosterone. By far the most 
important reason for such few transdermal delivery systems is the fact that human 
skin is highly impermeable for most drug compounds. Previously, many attempts 
have been made and many methods have been employed in order to improve drug 
delivery across the intact human skin (22).  
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Routes of drug penetration:  
             Drugs applied to the skin surface can serve two purposes. Dermal delivery is 
aimed at treating localized skin diseases. In this case, it is required that the drug 
penetrates the outer skin layers it reach its site of action within the skin, with little or 
no systemic uptake. On the other hand, transdermal delivery systems are designed to 
obtain therapeutic systemic blood levels. Hence, it is required that the drug reaches 
the dermal or transdermal drug delivery, the drug has to cross the outer layer of the 
skin, the stratum corneum. Since this layer is the main barrier of the skin, transport 
across the stratum corneum is the rate-limiting step in both dermal and transdermal; 
drug delivery. 
            There are two potential pathways for a molecule to across the stratum 
corneum: (a) the transappendagel route and (b) the transepidermal route (22). The 
transappendagel route involves transport of drugs via the sweat glands and the 
pilosebaceous units. This route bypasses the intact stratum corneum and is therefore 
also known as a “shunt” 
 Route. The transapendageal route, however, is not considered to be very significant, 
as the appendages only contribute 0.1% to the total surface area of the skin. Hence, 
transport of most of the drug compounds occurs via the transepidermal route, which 
involves transport across the intact contagious stratum corneum. Two path ways 
through the intact stratum corneum can be distinguished. (a) The intercellular route, 
crossing through the corneocytes and the intercytes and (b) The intercellular route has 
been thought to be the route of preference for most drug molecules. Hence, many 
techniques have been aimed to disrupt and weaken the highly organized intercellular 
lipid lamellae in an attempt to enhance drug transport across the intact skin. 
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Vesicle as skin delivery systems:              
            Vesicular Drug Delivery System is a novel approach having small spherical 
vesicles in which one or more aqueous compartments are completely enclosed by 
molecules that have hydrophilic and hydrophobic functionality such as phospholipids 
and cholesterol. These are varying in properties like composition, size, surface charge 
and method of preparation. They can be formed as single lipid bilayer or in multiple 
bilayer.These vesicular novel drug delivery systems are as a tool for the Dermal and 
Transdermal drug delivery.  
 
      Figure 2:                        Vesicle Formation  
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            One of the methods to enhance drug transport across the skin is the use of 
vesicles. Vesicles are hollow colloidal particles, consisting of amphilic molecules. 
These amphiphilic molecules consist of a polar hydrophilic head group and a polar 
hydrophobic tail. Due to their amphiphilic properties, these molecules can form in the 
presence of excess of water one (uni lamellar vesicles/0 or more (multilamellar 
vesicles) concentric bilayer that surround an equal number of aqueous compartments. 
Both water-soluble and water-insoluble drugs can be entrapped into the vesicles. 
Hydrophilic drugs can be entrapped into the internal aqueous compartment. While 
lipophillic drugs can be entrapped in the vesicle bilayer or partition between the 
bilayer and the aqueous phase (22). 
 
   Figure 3:                            Vesicle structure  
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           A wide variation of lipids and surfactants can be used to prepare vesicles. Most 
commonly, the vesicles are composed of phospholipids or non-ionic surfactants. 
These are referred to as liposomes and niosomes or non-ionic surfactants vesicles. 
The composition of the vesicles influences their physicochemical characteristics such 
as size, charge, phase state, lamellarity, and bilayer elasticity. These physicochemical 
characteristics in turn have a significant effect on the behaviour of the vesicles and 
hence also on their effectiveness as a drug delivery system 
 
The rationale for using vesicles in dermal and transdermal drug delivery is manifold: 
¾ Vesicles might act as drug carriers to deliver entrapped drug molecules into or 
across the skin. 
¾ Vesicles might act as penetration enhancers owing to the penetration of the 
individual lipid components into the stratum corneum and subsequently the 
alteration of the intercellular lipid lamellae within the skin layer. 
¾ Vesicles might serve as a depot for sustained release of dermal active 
compounds. 
¾ Vesicles might serve as a rate-limiting membrane barrier for the modulation of 
systemic absorption, hence providing a controlled transdermal delivery 
system. 
¾ The individual components of vesicles might have additional useful properties. 
¾ Vesicles biodegradable, minimally toxic, and relatively nonimmunogenic. 
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            To pursue optimal drug action, functional molecules could be transported by a 
carrier to the site of action and released to perform their task. Non-ionic surfactant 
vesicles known as niosomes are microscopic lamellar structures formed on admixture of  
a non-ionic surfactant, cholesterol and dicetyl phosphate with subsequent hydration in 
aqueous media. Niosomes are unilamellar or multilamellar vesicles of entrapping 
hydrophilic and hydrophobic solutes. These Niosomes can entrap solutes are quite 
stable, and require no special conditions and lack of many disadvantages associated with 
liposomes. 
           These Niosomes exhibit good chemical stability during storage, but there may be 
problems of physical instability in niosome dispersions, and thus limiting the shelf life 
of the dispersion.  
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   PRONIOSOMES AS A VESICULAR DRUG DELIVERY SYSTEM 
 
          A novel approach to minimize the physical instability of niosomes is 
Proniosomes - derived niosomes for the delivery of poorly soluble drugs. This is 
based on liposome production method. These Proniosomes consist of maltodextrin 
powder coated with surfactant or a surfactant/drug mixture to yield a dry powder. 
Upon addition of hot water and brief agitation, the maltodextrin dissolves and the 
surfactant forms a suspension of multilamellar vesicles (niosomes) containing the 
poorly soluble drug. The niosomes slowly release drug in to solution (3). The 
proniosome powder can also be mixed with hydrogel powder. Adding hot water to the 
mixed powders allow formation of a hydrogel in which niosomes spontaneously 
form. The niosome-containing hydrogel can be formed as a gel that will degrade and 
release intact niosomes or as a stable gel, which slowly releases the drug from 
niosomes that remain in side the gel matrix. 
                Proniosomes offer a versatile vesicle drug delivery concept with potential 
for delivery of drugs via transdermal route. This would be possible if Proniosomes 
form niosomes upon hydration with water from skin following topical application 
under occlusive conditions (1).  
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                Figure 4:          Proniosomes Methodology 
         
 
 
        Proniosomes minimizes problems of niosomes physical stability such as 
aggregation, fusion and leaking and provide additional convenience in transportation, 
storage and dosing. Transdermal therapeutic system has generated an interest as this 
system provides the considerable advantage of a non-invasive parenteral route for 
drug therapy, avoidance of first pass gut and hepatic metabolism, decreased side 
effects and relative ease of drug input termination in problematic cases (2). 
       Proniosomes are mostly used and interested in topical formulations. While using 
topical formulations (creams, gel) less potent drugs are used for the prevention of 
atrophy (skin thin and fragile). 
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Dermatitis: 
           Dermatitis is a blanket term meaning any “inflammation of the skin” (e.g. 
rashes, etc.) there are several different types of dermatitis. The different kinds usually 
have in common an allergic reaction to specific allergens. The term may be used to 
refer to eczema, which is also known as dermatitis eczema or eczematous dermatitis. 
A diagnosis of eczema often implies childhood or dermatitis, but without proper 
context, it means nothing more than a “rash”  
Types of Dermatitis 
Spongiotic dermatitis: 
           This pattern of skin reaction includes many other subtypes - irritant dermatitis, 
seborrheic dermatitis, atopic dermatitis, allergic contact dermatitis, thermal induced 
dermatitis, and drug induced dermatitis. 
Childhood eczema: 
           Also known as atopic dermatitis or atopic eczema. This can be immunologic 
mediated dermatitis. In dogs, it is frequently associated with airborne allergen or food 
allergen. In human, it can be associated with food allergy. However, most cases of 
human atopic dermatitis do not have an associated allergy. It is believed that the 
human skin is lacking in a protective lipid agent, making the skin itchy and prone to 
scratching. 
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Seborrhoeic dermatitis: 
           Seborrhoeic dermatitis is also known as dandruff. A rash of the scalp, face, and 
occasionally chest and groin. It is associated with a common yeast, Pityrosporum. It is 
treated with either an antiinflammatory or an antifungal agent, or both. 
Psoriasis: 
          Psoriasis or psoriatic dermatitis is a pattern of dermatitis with distinct 
relationship to a defined entity, psoriasis. It can be familial, and is associated with 
arthritis. 
Dyshidrotic dermatitis: 
           Dyshidrotic dermatitis is also known as Pompholyx. It is a pattern of 
spongiotic dermatitis presenting as small fluid filled or pus filled bumps on the hands 
and feet. The cause is unknown, but it has been highly associated with contact 
dermatitis (see Allergic Contact Dermatitis). Some cases are due to a food intolerance 
to nickel. 
Urticaria: 
         Urticaria is also known as hives and is a pattern of allergic dermatitis 
characterized by transient wheals or welts. The definition requires that the lesions 
shifts, moves, or changes within 24 hours. They should not remain static, or the 
diagnosis of urticaria can not be rendered. 
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Vesicular or bullous dermatitis: 
         This can be caused by drug reaction, or auto immune diseases. Examples 
includes Steven Johnson Syndrome, bullous erythema multiforme, bullous 
pemphigoid, and pemphigus vulgaris. Athlete foot fungus can also cause bullous 
dermatitis of the foot. 
Papular urticaria: 
         A pattern of dermatitis often presenting after insect bite reactions. Flea bite 
dermatitis are often grouped around the ankles in a walking adult. In a crawling 
infant, it can be anywhere on the body. 
         Eczema is a form of dermatitis, or inflammation of the epidermis. The term 
eczema is broadly applied to a range of persistent skin conditions. These include 
dryness and recurring skin rashes which are characterized by one or more of these 
symptoms: redness, skin edema (swelling), itching and dryness, crusting, flaking, 
blistering, cracking, oozing, or bleeding. Areas of temporary skin discoloration may 
appear and are sometimes due to healed lesions, although scarring is rare. In contrast 
to psoriasis, eczema is often likely to be found on the flexor aspect of joints. 
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Eczema 
 
Figure - 5 
  Medications: 
           Dermatitis is often treated by glucocorticoid (a corticosteroid) ointments, 
creams or lotions. They do not cure eczema, but are highly effective in controlling or 
suppressing symptoms in most cases. Dermatitis is often treated by glucocorticoid (a 
corticosteroid) ointments, creams or lotions. They do not cure eczema, but are highly 
effective in controlling or suppressing symptoms in most cases. 
            For mild-moderate eczema a weak steroid may be used (e.g. hydrocortisone or 
desonide), whilst more severe cases require a higher-potency steroid (e.g. clobetasol 
propionate, fluocinonide). Medium-potency corticosteroids such as clobetasone 
butyrate (Eumovate), Betamethasone Valerate (Betnovate) or triamcinolone are also 
available. Generally medical practitioners will prescribe the less potent ones first 
before trying the more potent ones. 
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        Prolonged use of topical corticosteroids is thought to increase the risk of possible 
side effects, the most common of which is the skin becoming thin and fragile 
(atrophy).[6] Because of this, if used on the face or other delicate skin, only a low-
strength steroid should be used. 
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                               LITERATURE REVIEW  
 
¾ Yi-Hung Tsai a., et al., investigated the estradiol skin permeation from 
various proniosome gel formulations across excised rat skin in in-vitro 
studies. The encapsulation efficiency and size of niosomal vesicles formed 
from Proniosomes upon hydration were also characterized. The 
encapsulation (%) of Proniosomes with Span surfactants showed a very 
high value of ¥100%. Proniosomes with Span 40 and Span 60 increased 
the permeation of estradiol across skin. Both penetration enhancer effect of 
non-ionic surfactant and vesicle-skin interaction may contribute to the 
mechanisms for Proniosomes to enhance estradiol permeation. Niosome 
suspension (diluted Proniosomal formulations) and proniosome gel 
showed different behavior in modulating transdermal delivery of estradiol 
across skin. Presence or absence of cholesterol in the lipid bilayers of 
vesicles did not reveal difference in encapsulation and permeation of the 
associated estradiol. The types and contents of non-ionic surfactant in 
Proniosomes are important factors affecting the efficiency of transdermal 
estradiol delivery. 
¾ Ankur Gupta., et al., studied on development of a proniosomal carrier 
system for captopril for the treatment of hypertension that is capable of 
efficiently delivering entrapped drug over an extendedperiod of time. The 
potential of proniosomes as a transdermal drug delivery system for 
captopril was investigated by encapsulating the drug in various 
formulations of proniosomal gel composed of various ratios of sorbitan 
fatty acid esters, cholesterol, lecithin prepared by coacervation-phase 
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separation method. The formulated systems were characterized in vitro for 
size, vesicle count, drug entrapment, drug release profiles and vesicular 
stability at different storage conditions. Stability studies for proniosomal 
gel were carried out for 4 weeks. The method of proniosome loading 
resulted in an encapsulation yield of 66.7 - 78.7%. Proniosomes were 
characterised by transmission electron microscopy. In vitro studies showed 
prolonged release of entrapped captopril. At refrigerated conditions, higher 
drug retention was observed. It is evident from this study that proniosomes 
are a promising prolonged delivery system for captopril and have 
reasonably good stability characteristics.  
¾ Almira I. Blazek-Welsh and David G. Rhodes., et al., investigated on 
moaltodextrin Proniosomes. The Niosomes are nonionic surfactant 
Vesicles that have potential applications in the delivery of hydrophobic or 
amphiphilic drugs. Our lab developed Proniosomes, a dry formulation 
using a sorbitol carrier coated with nonionic surfactant, which can be used 
to produce niosomes within minutes by the addition of hot water followed 
by agitation. The sorbitol carrier in the original proniosomes was soluble 
in the solvent used to deposit surfactant, so preparation was tedious and 
the dissolved sorbitol interfered with the encapsulation of one model drug. 
A novel method is reported here for rapid preparation of proniosomes with 
a wide range of surfactant loading. A slurry method has been developed to 
produce proniosomes using maltodextrin as the carrier. The time required 
to produce proniosomes by this simple method is independent of the ratio 
of surfactant solution to carrier material and appears to be scalable. The 
flexibility of the proniosome preparation method would allow for the 
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optimization of drug encapsulation in the final formulation based on the 
type and amount of maltodextrin. This formulation of proniosomes is a 
practical and simple method of producing niosomes at the point of use for 
drug delivery. 
¾ Jain. N.K., et al., investigated on development of proniosome based 
transdermal drug delivery system of levonorgestrel (LN) and extensively 
characterized both in vitro and in vivo. The proniosomal structure was 
liquid crystalline-compact niosomes hybrid which could be converted into 
niosomes upon hydration. The system was evaluated in vitro for drug 
loading, rate of hydration (spontaneity), vesicle size, polydispersity, 
entrapment efficiency and drug diffusion across rat skin. The effect of 
composition of formulation, amount of drug, type of Spans, alcohols and 
sonication time on transdermal permeation profile was observed. The 
stability studies were performed at 48C and at room temperature. The 
biological assay for progestational activity included endometrial assay and 
inhibition with the formation of corpora lutea. The study demonstrated the 
utility of proniosomal transdermal patch bearing levonorgestrel for 
effective contraception. 
¾ Ibrahim A. Alsarra., et al., studied whether Niosomes are nonionic 
surfactant vesicles that have potential applications in the delivery of 
hydrophobic and hydrophilic drugs. Permeation of a potent nonsteroidal 
anti-inflammatory, ketorolac, across excised rabbit skin from various 
proniosome gel formulations was investigated using Franz diffusion cells. 
Each of the prepared proniosomes significantly improved drug permeation 
and reduced the lag time (P! 0.05). Proniosomes prepared with Span 60 
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provided a higher ketorolac flux across the skin than did those prepared 
with Tween 20 (7- and 4-fold the control, respectively). A change in the 
cholesterol content did not affect the efficiency of the proniosomes, and 
the reduction in the lecithin content did not significantly decrease the flux 
(PO0.05). The encapsulation efficiency and size of niosomal vesicles 
formed by proniosome hydration were also characterized by specific high 
performance liquid chromatography method and scanning electron 
microscopy. Each of the prepared niosomes achieved about 99% drug 
encapsulation. Vesicle size was markedly dependent on the composition of 
the proniosomal formulations. Proniosomes may be a promising carrier for 
ketorolac and other drugs, especially due to their simple production and 
facile up 
¾ Ajay B. Solanki., et al., investigate the combined influence of 3 
independent variables in the preparation of piroxicam proniosomes by the 
slurry method. A 3-factor, 3-level Box-Behnken design was used to derive 
a secondorder polynomial equation and construct contour plots to predict 
responses. The independent variables selected were molar ratio of Span 
60: cholesterol (X1), surfactant loading (X2), and amount of drug (X3). 
Fifteen batches were prepared by the slurry method and evaluated for 
percentage drug entrapment (PDE) and vesicle size. The transformed 
values of the independent variables and the PDE (dependent variable) were 
subjected to multiple regressions to establish a full-model second-order 
polynomial equation. F was calculated to confirm the omission of 
insignificant terms from the full-model equation to derive a reduced-model 
polynomial equation to predict the PDE of proniosome-derived niosomes. 
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Contour plots were constructed to show the effects of X1, X2 and X3 on 
the PDE. A model was validated for accurate prediction of the PDE by 
performing checkpoint analysis. The computer optimization process and 
contour plots predicted the levels of independent variables X1, X2, and X3 
(0, -0.158 and –0.158 respectively), for maximized response of PDE with 
constraints on vesicle size. The Box-Behnken design demonstrated the role 
of the derived equation and contour plots in predicting the values of 
dependent variables for the preparation and optimization of piroxicam 
proniosomes. 
¾ El-laithy. H.M., et al., investigated on development of Novel approach for 
the preparation of controlled release proniosome-derived niosomes, using 
sucrose stearate as non-ionic biocompatible surfactants for the nebulisable 
delivery of cromolyn sodium. Conventional niosomes were prepared by a 
reverse phase evaporation method followed by the preparation of 
proniosomes by spraying the optimized surfactant–lipid mixture of sucrose 
stearate, cholesterol and stearylamine in 7:3:0.3 molar ratios onto the 
surface of spray dried lactose powder. Proniosome-derived niosomes were 
obtained by hydrating proniosomes with 0.9% saline at 50 ◦C and mixing 
for approximately 2 min. All vesicles were evaluated for their particle size, 
morphological characteristics, entrapment efficiency, in vitro drug release, 
nebulisation efficiency and physical stability at 2–8 ◦C. In addition, 
coating carrier surface with the surfactant–lipid mixture, during 
preparation of proniosomes, resulted in smaller, free flowing, homogenous 
and smooth vesicles with high drug entrapment efficiency. Compared to a 
standard drug solution, a successful retardation of the drug release rate was 
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achieved with the proniosome-derived niosomes, where the t50% value of 
the release profile was 18.1 h compared to 1.8 h. Moreover, high 
nebulisation efficiency percentage and good physical stability were also 
achieved. The results are very encouraging and offer an alternative 
approach to minimize the problems associated with conventional niosomes 
like degradation, sedimentation, aggregation and fusion 
¾ Vyas. S.P., et al., studied on topical drug delivery through vesicular 
systems. DNA vaccines are capable of eliciting both humoral as well as 
cellular immune responses. Liposomes have been widely employed for 
DNA delivery through topical route; however, they suffer from certain 
drawbacks like higher cost and instability. In present study, non-ionic 
surfactant based vesicles (niosomes) for topical DNA deliveries have been 
developed. DNA encoding hepatitisB surface antigen (HBsAg) was 
encapsulated in niosomes. Niosomes composed of span 85 and cholesterol 
as constitutive lipids were prepared by reverse phase evaporation method. 
Prepared niosomes were characterized for their size, shape and entrapment 
efficiency. The immune stimulating activity was studied by measuring 
serum anti-HBsAg titer and cyokines level (IL-2 and IFN-_) following 
topical application of niosomes in Balb/c mice and results were compared 
with naked DNA and liposomes encapsulated DNAapplied topically as 
well as naked DNA and pure recombinant HBsAgadministered 
intramuscularly. It was observed that topical niosomes elicited a 
comparable serum antibody titer and endogenous cytokines levels as 
compared to intramuscular recombinant HBsAg and topical liposomes. 
The study signifies the potential of niosomes as DNA vaccine carriers for 
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effective topical immunization. The proposed system is simple, stable and 
cost effective compared to liposomes. 
¾ Suresh P. Vyasa, et al., study results shows that, Non-invasive vaccine 
delivery is a top priority for public health agencies because conventional 
immunization practices are unsafe and associated with numerous 
limitations. Recently, the skin has emerged as a potential alternative route 
for non-invasive delivery of vaccine. Topical immunization (TI), 
introduction of antigen through topical application onto the intact skin, has 
many practical merits compared to injectable routes of administration. One 
of the possibilities for increasing the penetration of bioactives through the 
skin is the use of vesicular systems. Specially designed lipid vesicles are 
attracting intense attention and can be used for non-invasive antigen 
delivery. In the present study, elastic vesicle transfersomes, non-ionic 
surfactant vesicles (niosomes) and liposomes were used to study their 
relative potential in non-invasive delivery of tetanus toxoid (TT). 
Transfersomes, niosomes and liposomes were prepared and characterized 
for shape, size and entrapment efficiency. These vesicles were extruded 
through polycarbonate filter (50-nm pore size) to assess the elasticity of 
the vesicles. The immune stimulating activity of transfersomes, niosomes 
and liposomes were studied by measuring the serum anti-TT IgG titre 
following topical immunization. The immune response elicited by topical 
immunization was compared with that elicited by same dose of alum-
adsorbed tetanus toxoid (AATT) given intramuscularly. The results 
indicate that optimal formulations of transfersomes, niosomes and 
liposomes could entrap 72.7±3.4, 42.5±2.4 and 41.3±2.2% of antigen and 
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their elasticity values were 124.4±4.2, 29.3±2.4 and 21.7±1.9, respectively. 
In vivo study revealed that topically given TT containing transfersomes, 
after secondary immunization, could elicit immune response (anti-TT-IgG) 
that was equivalent to one that produced following intramuscularly alum-
adsorbed TT-based immunization. In comparison to transfersomes, 
niosomes and liposomes elicited weaker immune response. Thus 
transfersomeshold promise for effective non-invasive topical delivery of 
antigen(s). 
¾ Chang-Koo Shim., et al., investigated the feasibility of proliposomes as a 
sustained transdermal dosage form was examined. Proliposomes 
containing varying amount of nicotine were prepared by a standard method 
using sorbitol and lecithin. The porous structure of sorbitol in the 
proliposomes was maintained, indicating that the majority of lecithin and 
nicotine is deposited within their porous matrix of the sorbitol particles. As 
a consequence, the flow property of the proliposome particles was 
comparable to that of original sorbitol particles. Microscopic observation 
revealed that proliposomes are converted to liposomes almost completely 
within minutes following contact with water. It indicates that proliposomes 
may form liposomes by the sweat when they are applied on the skin under 
occlusive conditions in vivo. The size distribution of the reconstituted 
liposomes and nicotine release to pH 7.4 phosphate buffer from them were 
not significantly affected by the content of nicotine. The release pattern 
was apparently identical to the ExodusÒ patch, a commercially available 
transdermal nicotine formulation. We also studied in vitro permeation of 
nicotine across rat skin from proliposomes in a modified Keshary–Chien 
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diffusion cell where the experimental set up simulates in vivo application 
of the proliposomes under an occlusive condition. The nicotine flux from 
proliposomes was initially retarded compared with that of nicotine powder. 
The flux from proliposomes appeared to remain constant throughout the 
experimental period compared with that of nicotine powder, indicating that 
nicotine may be delivered across the skin in a sustained manner at a 
constant rate from proliposomes. These results, therefore, indicate that 
sustained transdermal delivery of nicotine is feasible using proliposomal 
formulations if the formulations are topically applied under occlusive 
conditions. 
¾ Katare. O.P., et al., investigated the Dithranol is one of the mainstays in 
the topical treatment of psoriasis. However, the use of dithranol in 
psoriatic condition is inconvenient and troublesome, as it has irritating, 
burning, staining and necrotizing effect on the normal as well as the 
diseased skin. The entrapment of drug in vesicles is viewed to help in the 
localized delivery of the drug and an improved availability of the drug at 
the site will reduce the dose and in turn, the dose-dependent side effects 
like irritation and staining. The investigations deal with critical parameters 
controlling the formulation and stabilization of dithranol loaded liposomes 
and niosomes. The entrapment efficiency of dithranol in liposomes was 
optimized by altering the proportion of phosphatidyl choline and 
cholesterol, and in case of niosomes it was between Span 60 and 
cholesterol. Hydration and permeation mediums were also established 
keeping in view the poor solubility and stability of dithranol. The mean 
liposome and niosomes sizes were 4_1.25 and 5_1.5 _m, respectively. The 
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drug-leakage study carried out at different temperatures of 4–8, 25_2 and 
37 °C for a period of two months affirms that the drug leakage increased at 
a higher temperature. The in vitro permeation study using mouse 
abdominal skin shows significantly enhanced permeation with vesicles as 
indicated by flux of dithranol from liposomes (23.13 _g/cm2/h) and 
niosomes (7.78 _g/cm2/h) as compared with the cream base (4.10 
_g/cm2/h). 
¾ Barry. B.W., et al., studied on optimization of drug delivery through 
human skin is important in modern therapy. This review considers drug–
vehicle interactions (drug or prodrug selection, chemical potential control, 
ion pairs, coacervates and eutectic systems) and the role of vesicles and 
particles (liposomes, transfersomes, ethosomes, niosomes).We can modify 
the stratum corneum by hydration and chemical enhancers, or bypass or 
remove this tissue via microneedles, ablation and follicular delivery. 
Electrically assisted methods (ultrasound, iontophoresis, electroporation, 
magnetophoresis and photomechanical waves) show considerable promise. 
Of particular interest is the synergy between chemical enhancers, 
ultrasound, iontophoresis and electroporation. 
¾ Jia-You Fang., et al., investigate the skin permeation and partitioning of a 
fluorinated quinolone antibacterial agent, enoxacin, in liposomes and 
niosomes, after topical application, were elucidated in the present study. In 
vitro percutaneous absorption experiments were performed on nude mouse 
skin with Franz diffusion cells. The influence of vesicles on the 
physicochemical property and stability of the formulations were measured. 
The enhanced delivery across the skin of liposome and niosome 
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encapsulated enoxacin had been observed after selecting the appropriate 
formulations. The optimized formulations could also reserve a large 
amount of enoxacin in the skin. A significant relationship between skin 
permeation and the cumulative amount of enoxacin in the skin was 
observed. Both permeation enhancer effect and direct vesicle fusion with 
stratum corneum may contribute to the permeation of enoxacin across 
skin. Formulation with niosomes demonstrated a higher stability after 48 h 
incubation compared to liposomes. The inclusion of cholesterol improved 
the stability of enoxacin liposomes according to the results from 
encapsulation and turbidity. However, adding negative charges reduced the 
stability of niosomes. The ability of liposomes and niosomes to modulate 
drug delivery without significant toxicity makes the two vesicles useful to 
formulate topical enoxacin.  
¾ David G. Rhodes., et al., study described a procedure for producing a dry 
product which may be hydrated immediately before use to yield aqueous 
niosome dispersions similar to those produced by more cumbersome 
conventional methods. These ‘proniosomes’ minimize problems of 
niosome physical stability such as aggregation, fusion and leaking, and 
provide additional convenience in transportation, distribution, storage, and 
dosing. This report describes the preparation of dispersions of proniosome-
derived niosomes, comparison of these niosomes to conventional 
niosomes, and optimization of proniosome formulations. In addition, 
conventional and proniosome-derived niosomes are compared in terms of 
their morphology, particle size, particle size distribution, and drug release 
performance in synthetic gastric or intestinal fluid. In all comparisons, 
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proniosome-derived niosomes are as good as or better than conventional 
niosomes.  
¾ J. Kristla., et al., studied the influence of liposome size on the transport of 
hydrophilic substance. The relative contribution of the liposome size, 
lamellarity, composition and charge to transport drug into the skin, which 
was applied entrapped in liposomes, is a subject of some controversy. For 
this purpose liposomes composed of dipalmitoyl-phosphatidylcholine 
(DPPC), or non-hydrogenated soya lecithin (NSL) or hydrogenated soya 
lecithin (HSL), all in combination with 30% cholesterol, as well as of two 
types of niosomes: from glyceryl distearate or PEG stearate in combination 
with 45% of cholesterol and 10% of lipoaminosalt were prepared and their 
physical characteristics (size, polydispersity index, zeta potential, 
entrapped volume) were determined. Their size was varied by extrusion 
and by sonication. The transport of the entrapped spin labeled hydrophilic 
compounds into the skin was measured by electron paramagnetic 
resonance imaging methods. No significant transport into the deeper skin 
layers (more than 100 mm deep) was observed for NSL liposomes, 
irrespective of vesicle size. For all other vesicular systems some transport 
into the deeper skin layers was observed, which did not depend on vesicle 
size, significantly until the vesicle diameter of approximately 200 nm was 
reached. However, for small vesicles (with diameter less than 200 nm) the 
transport is significantly decreased.We have proven that small vesicles are 
not stable and disintegrate immediately in contact with other surfaces. As a 
consequence, they lose an important influence on the topical delivery of 
the entrapped hydrophilic substances. 
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¾ Işık Sarıgüllü Özgüney, Hatice Yeşim Karasulu., et al.  Study was to 
evaluate and compare the in vitro and in vivo transdermal potential of w/o 
microemulsion (M) and gel (G) bases for diclofenac sodium (DS). The 
effect of dimethyl sulfoxide (DMSO) as a penetration enhancer was also 
examined when it was added to the M formulation. To study the in vitro 
potential of these formulations, permeation studies were performed with 
Franz diffusion cells using excised dorsal rat skin. To investigate their in 
vivo performance, a carrageenan-induced rat paw edema model was used. 
The commercial formulation of DS (C) was used as a reference 
formulation. The results of the in vitro permeation studies and the paw 
edema tests were analyzed by repeated-measures analysis of variance. The 
in vitro permeation studies found that M was superior to G and C and that 
adding DMSO to M increased the permeation rate. The permeability 
coefficients (Kp) of DS from M and M+DMSO were higher (Kp = 4.9 × 
10−3 ± 3.6 × 10−4 cm/h and 5.3 × 10−3 ± 1.2 × 10−3 cm/h, respectively) 
than the Kp of DS from C (Kp = 2.7 × 10−3 ± 7.3 × 10−4 cm/h) and G (Kp 
= 4.5 × 10−3 ± 4.5 × 10−5 cm/h). In the paw edema test, M showed the 
best permeation and effectiveness, andM+DMSO had nearly the same 
effect as M. The in vitro and in vivo studies showed that M could be a 
new, alternative dosage form for effective therapy. 
¾ Robert C. Scott, Paul H. Dugard., et al., investigated the absorption of 
undiluted phthalate diesters (dimethyl phthalate (DMP), diethyl phthalate 
(DEP), dibutyl phthalate (DBP) and di-(-2-ethylhexyl) phthalate (DEHP)] 
has been measured in vitro through human and rat epidermal membranes. 
Epidermal membranes were set up in glass diffusion cells and their 
                                 37
permeability to tritiated water measured to establish the integrity of the 
skin before the phthalate esters were applied to the epidermal surface. 
Absorption rates for each phthalate ester were determined and a second 
tritiated water permability assessment made to quantify any irreversible 
alterations in barrier function due to contact with the esters. Rat skin was 
consistently more permeable to phthalate esters than the human skin. As 
the estersbecame more lipophillic and less hydrophilic, the rate of 
absorption was reduced. Contact with the esters caused little change in the 
barrier properties of human skin, but caused marked increases in the 
permeability to water of rat skin. Although differences were noted between 
species, the absolute rates of absorption measured indicate that the 
phthalate esters are slowly absorbed through both human and rat skin. 
¾ Sushama talegaonkar., et al., investigated on development of novel drug 
delivery system. Novel drug delivery system aims to deliver the drug at a 
rate directed by the needs of the body during the period of treatment, and 
channel the active entity to the site of action. At present, no available drug 
delivery system behaves ideally achieving all the lofty goals, but sincere 
attempts have been made to achieve them through novel approaches in 
drug delivery. A number of novel drug delivery systems have emerged 
encompassing various routes of administration, to achieve controlled and 
targeted drug delivery. Encapsulation of the drug in vesicular structures is 
one such system, which can be predicted to prolong the existence of the 
drug in systemic circulation, and reduce the toxicity, if selective uptake 
can be achieved. Consequently a number of vesicular drug delivery 
systems such as liposomes, niosomes, transfersomes, and pharmacosomes  
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were developed. Advances have since been made in the area of vesicular 
drug delivery, leading to the development of systems that allow drug 
targeting, and the sustained or controlled release of conventional 
medicines. The focus of this review is to bring out the application, 
advantages, and drawbacks of vesicular systems. 
¾ Hamidreza Moghimi., et al., studied the Nicotine transdermal systems 
are being used as an aid to smoking cessation programs. As the kinetics of 
nicotine delivery is important in success of a smoking cessation program, 
rapid and high input of nicotine is required, which is not possible by 
passive methods and requires enhancement strategies such as 
iontophoresis. Iontophoretic permeation, of nicotine looks promising, 
based on published data on human skin. However, to optimize this method, 
permeation pathways should be known and further parameters have to 
studied, which are the subject of the present investigation. In this study 
iontophoretic permeation of nicotine through rat skin was performed and 
the effects of different variables on this phenomenon were studied. Anodic 
iontophoresis of nicotine from a solution at pH 2.8, using a 0.5 mA/cm2 
current density resulted in a considerable enhancement (about 3-fold) of 
nicotine absorption through rat skin. Nicotine concentration and current 
density showed a directly increasing effect on permeation of the drug, but 
the effect of concentration was not linear. Pulsatile current delivery was 
more effective in permeation of nicotine than the continuous method. 
Anodic iontophoresis was around 2-fold more effective than the cathodic 
method in increasing the flux. Post iontophoretic permeation studies 
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showed good reversibility of the membrane barrier properties. Results 
were in good agreement with the reported human data and might be 
considered as an evidence of the ability of rat skin to model human skin 
and also the importance of intercellular pathway of the stratum corneum in 
iontophoretic delivery of nicotine and possibly other drugs. Donor's pH 
showed no effect on permeation of nicotine under the studied conditions, 
pH values of <3. Results also showed that the electr-osmotic flow could 
occur at pH values lower than 4. Finally, this study show that by 
controlling the effective parameters of iontophoretic delivery, a more 
effective nicotine transdermal delivery method would achievable. 
 
 
 
 
 
 
 
 
                                 40
 
PROFILE OF THE DRUG USED IN THIS STUDY 
                                       HYDROCORTISONE 
         Hydrocortisone Short-acting glucocorticoid that depresses formation, release, 
and activity of endogenous mediators of inflammation including prostaglandins, 
kinins, histamine, liposomal enzymes, and complement system. Also modifies body's 
immune response (24)   
        Hydrocortisone is a topical corticosteroids constitute of primarily synthetic 
steroids used as anti-inflammatory and anti-pruritic agents 
    SYNONYM:   Pregn-4-ene-3, 20-dione, 11, 17, 21-trihydroxy-, (11ß)-)         
    Molecular formula:  C21H30O5 
    Molecular weight   :  362.46  
   Potency            :  0.004-0.005 µg/ml 
   Melting Point     : 211-214 °C (lit.) 
  Chemical Structure: 
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CLINICAL PHARMACOLOGY: 
                Topical corticosteroids share anti-inflammatory, antipruritic and 
vasoconstrictive actions. 
                The mechanism of anti-inflammatory activity of the topical corticosteroids 
is unclear. Various laboratory methods, including vasoconstrictor assays, are used to 
compare and to predict potencies and/or clinical efficacies of the topical 
corticosteroids. There is some evidence to suggest that a recognizable correlation 
exists between vasoconstrictor potency and therapeutic efficacy in man (25).  
Pharmacokinetics:  
               The extent of percutaneous absorption of topical corticosteroids is 
determined by many factors including the vehicle, the integrity of the epidermal 
barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed 
from normal intact skin. Inflammation and/or other disease processes in the skin 
increase percutaneous absorption. Occlusive dressings substantially increase the 
percutaneous absorption of topical corticosteroids.  
               Thus, occlusive dressings may be a valuable therapeutic adjunct for 
treatment of resistant dermatoses. Once absorbed through the skin, topical 
corticosteroids are handled through pharmacokinetic pathways similar to systemically 
administered corticosteroids. Corticosteroids are bound to plasma proteins in varying 
degrees. Corticosteroids are metabolized primarily in the liver and are then excreted 
by the kidneys. Some of the topical corticosteroids and their metabolites are also 
excreted into the bile (25).  
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INDICATIONS AND USAGE 
              Topical corticosteroids are indicated for the relief of the inflammatory and 
pruritic manifestations of corticosteroid-responsive dermatoses. 
DIFFERENT  DERMATITIS 
        
Figure 6 
CONTRAINDICATIONS 
              Topical corticosteroids are contraindicated in those patients with a history of 
hypersensitivity to any of the components of the preparation.  
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ADVERSE REACTIONS 
              The following local adverse reactions are reported infrequently with topical 
corticosteroids, but may occur more frequently with the use of occlusive dressings. 
 These reactions are listed in approximate decreasing order of occurrence:        
              Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform 
eruptions, hypo pigmentation, perioral dermatitis, allergic contact dermatitis, 
maceration of the skin, secondary infection, skin atrophy, striae and miliaria (25).  
OVERDOSAGE 
              Topically applied corticosteroids can be absorbed in sufficient amounts to 
produce systemic effects. 
DOSAGE AND ADMINISTRATION 
              Topical corticosteroids are generally applied to the affected area as a thin 
film from 2 to 4 times daily depending on the severity of the condition.  
              Occlusive dressings may be used for the management of psoriasis or 
recalcitrant conditions.  If an infection develops, the use of occlusive dressings should 
be discontinued and appropriate antimicrobial therapy instituted.  
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                                    Polymer profile 
 Lecithin biochemistry also called Phosphatidyl Choline:  
           Any of a group of phospholipids (phosphoglycerides) that is important in cell 
structure and metabolism. Lecithins are composed of phosphoric acid, cholines, esters 
of glycerol, and two fatty acids; the chain length, position, and degree of unsaturation 
of these fatty acids vary, and this variation results in different lecithin with different 
biological functions. 
            Pure lecithin is white and waxy and darkens when exposed to air. Commercial 
lecithin is brown to light yellow, and its consistency varies from plastic to liquid. 
           The term lecithin is also used for a mixture of phosphoglycerides containing 
principally lecithin, cephalin (specifically phosphatidyl ethanolamine), and 
phosphatidyl inositol.  
           Commercial lecithin, most of which comes from soybean oil, contains this 
mixture and, commonly, about 35 percent neutral oil. It is widely used as a wetting 
and emulsifying agent and for other purposes. Among the products in which it is used 
are animal feeds, baking products and mixes, chocolate, cosmetics and soaps, dyes, 
insecticides, paints, and plastics. 
Scientific names: 1,2-diacyl-sn-glycero-3-phosphatidylcholine 
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            Lecithin is usually used as synonym for phosphatidylcholine, a phospholipid 
which is the major component of a phosphatide fraction which may be isolated from 
either egg yolk or soy beans. It is commercially available in high purity as a food 
supplement and for medical uses.  
           Lecithin is regarded as a well tolerated and non-toxic emulsifier. It is approved 
by the United States Food and Drug Administration for human consumption with the 
status "Generally Recognized As Safe". Lecithin is an integral part of cell 
membranes, and can be totally metabolised, so it is virtually non-toxic to humans. 
Other emulsifiers can only be excreted via the kidneys.  
           Lecithin is used commercially for anything requiring a natural   emulsifier 
and/or lubricant, from pharmaceuticals to protective coverings. For example, lecithin 
is the emulsifier that keeps chocolate and cocoa butter in a candy bar from separating. 
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Sorbitan Esters (Sorbitan Fatty Acid Esters) 
Functional Category 
Emulsifying agent, non-ionic surfactant; solubilizing agent, wetting and 
dispersing/suspending agent (26).  
Span 20 
Non-proprietary Name:  Sorbitan monolaurate 
Synonym:  Arlacel 20; Armotan ML; Crill 1; Dehymuls SML; E493; Glycomul L; 
Hodag SML; Liposorb L; Montane 20; Protachem SML; Sorbester P12; Sorbirol L; 
sorbitan  laurate; Span 20; Tego SML. 
Chemical name:  Sorbitan monododecanoate 
 
Structure:  
                                
  
 
Empirical formula: C18H34O6 
Molecular weight:   346 
Colour and form: Yellow viscous liquid 
Safety: LD50 (rat, oral): 33.6 g/kg. 
             Experimental neoplastigen. 
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Span 40 
Non-proprietary Names:  Sorbitan monopalmitate 
Synonym: 1,4-Anhydro-D-glucitol, 6-hexadecanoate; Ablunol S-40; Arlacel 40; 
Armotan MP; Crill 2; Dehymuls SMP; E495; Glycomul P; Hodag SMP; Lamesorb 
SMP; Liposorb P; Montane 40; Nikkol SP-10; Nissan Nonion PP-40R; Protachem 
SMP; Proto-sorb SMP; Sorbester P16; Sorbirol P; sorbitan palmitate; Span 40. 
Chemical name:  Sorbitan monohexadecanoate 
Structure:  
                 
                                   
 
Empirical formula: C22H42O6 
Molecular weight:   403 
Colour and form:  Cream solid 
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Span 60 
Non-proprietary Name:  Sorbitan monostearate 
Synonym:  Ablunol S-60; Alkamuls SMS; 1,4-Anhydro-D-glucitol, 6-
octadecanoate; anhydrosorbitol monostearate; Arlacel 60; Armotan MS; Atlas 110K; 
Capmul S; Crill 3; Dehymuls SMS; Drewmulse SMS; Drewsorb 60K; Durtan 6O; 
Durtan 60K; E491; Famodan MS Kosher; Glycomul S FG; Glycomul S KFG; Hodag 
SMS; Lamesorb SMS; Liposorb S; Liposorb SC; Liposorb S-K; Montane 60; Nissan 
Nonion SP-60R; Norfox Sorbo S- 60FG; Polycon S60K; Protachem SMS; Prote-sorb 
SMS; S-Maz 60K; SMaz 60KHS; Sorbester P18; Sorbirol S; sorbitan stearate; Sorgen 
50; Span 60; Span 60K; Span 60 VS; Tego SMS. 
.Chemical name:   Sorbitan mono-octadecanoate 
Structure:  
                               
Empirical formula: C24H46O6 
Molecular weight:   431 
Colour and form: Cream solid 
Safety: LD50 (rat, oral): 31 g/kg. 
            Very mildly toxic by ingestion. Experimental reproductive effects. 
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Span 80 
Non-proprietary Name:  Sorbitan monooleate  
Synonym:  Ablunol S-80; Arlacel 80; Armotan MO; Capmul O; Crill 4; Crill 50; 
Dehymuls SMO; Drewmulse SMO; Drewsorb 80K; E494; Glycomul O; Hodag SMO; 
Lamesorb SMO; Liposorb O; Montane 80; Nikkol SO-10; Nissan Nonion OP-80R; 
Norfox Sorbo S-80; Polycon S80 K; Proto-sorb SMO; Protachem SMO; S-Maz 80K; 
Sorbester P17; Sorbirol O; sorbitan oleate; Sorgen 40; Sorgon S-40-H; Span 80; Tego 
SMO. 
Chemical name:   (Z)-Sorbitan mono-9-octadecenoate 
Structure:  
                             
 
Empirical formula:  C24H44O6 
Molecular weight:  429 
Colour and form: Yellow viscous liquid 
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Polyoxyethylene Sorbitan Fatty Acid Esters 
Functional Category 
Emulsifying agent, non-ionic surfactant, solubilizing agent, wetting, 
dispersing / suspending agent (26). 
Tween 40 
Non-proprietary Names: Polysorbate 40 
Synonym:  Crillet 2; E434; Eumulgin SMP; Glycosperse S-20; Hodag PSMP-20; 
Lamesorb SMP-20; Liposorb P-20; Lonzest SMP-20; Montanox 40; poly(oxy- 1,2-
ethanediyl) derivatives; Protasorb P-20; Ritabate 40; sorbitan monohexadecanoate; 
Sorbax PMP-20; Tween 40. 
Chemical name:   Polyoxyethylene 20 sorbitan monopalmitate 
Structure 
                                    
Empirical formula: C62H122O26  
Molecular weight: 1284 
Colour and form: Yellow oily liquid 
Solubility:  Soluble in water and ethanol. Insoluble in mineral oils 
Safety:  LD50 (rat, IV): 1.58 g/kg.  Moderately toxic by IV route. 
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Tween 60 
Non-proprietary Names:  Polysorbate 60 
Synonym 
 Atlas 70K; Atlas Armotan PMS 20; Capmul POE-S; Cremophor PS 60; 
Crillet3; Drewpone 60K; Durfax 60; Durfax 60K; E435; Emrite 6125; Eumulgin 
SMS; Glycosperse S-20; Glycosperse S-20FG; Glycosperse S-20FKG; Hodag PSMS-
20; Hodag SVS-18; Lamsorb SMS-20; Liposorb S-20; Liposorb S-20K; Lonzest 
SMS-20; Nikkol TS-10; Norfox SorboT-60 Montanox 60; Polycon T 60 K; 
polyoxyethylene 20 stearate; Ritabate 60; Protasorb S-20; Sorbax PMS-20; sorbitan 
monooctadecanoate poly(oxy-1,2-ethanediyl) derivatives; T-Maz 60; T-Max 60KHS; 
Tween 60; Tween 60K; Tween 60 VS (26). 
Chemical name:   Polyoxyethylene 20 sorbitan monostearate 
Structure:  
                            
Emprical formula: C64H126O26 
Molecular weight:  1312  
Colour and form:  Yellow oily liquid 
Solubility: Soluble in water and ethanol. Insoluble in mineral oils 
Safety: LD50 (rat, IV): 1.22 g/kg. Moderately toxic by IV route.  
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Tween 80 
Non-proprietary Names:  Polysorbate 80 
Synonym:  Atlas E; Armotan PMO 20; Capmul POE-O; Cremophor PS 80; Crillet 
4; Crillet 50; Drewmulse POE-SMO; Drewpone 80K; Durfax 80; Durfax 80K; E433; 
Emrite 6120; Eumulgin SMO; Glycosperse O-20; Hodag PSMO-20; Liposorb O-20; 
Liposorb O-20K; Montanox 80; polyoxyethylene 20 oleate; Protasorb O-20; Ritabate 
80; (Z)-sorbitan mono-9-octadecenoate poly(oxy1,2- ethanediyl) derivatives; Tego 
SMO 80; Tego SMO 80V; Tween 80(26). 
Chemical name:  Polyoxyethylene 20 sorbitan monooleate 
Structure:   
                          
Emprical formula:  C64H124O26 
Molecular weight:  1310 
Colour and form: Yellow oily liquid 
Solubility: Soluble in water and ethanol. Insoluble in mineral oils 
Safety: moderately toxic by IV route. Mildly toxic by ingestion. Eye irritation. 
Experimental tumorigen, reproductive effects.  
Mutogenic data.   · LD50 (mouse, IP): 7.6 g/kg 
                             · LD50 (mouse, IV): 4.5 g/kg 
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Cholesterol 
Non-proprietary Name: Cholesterol  
Synonyms: Cholesterin; cholesterolum. 
Chemical Name:  Cholest-5-en-β-ol [57-88-5] 
Empirical Formula: C27H46O 
Molecular Weight: 386.67 
Structure 
                                 
Functional Category 
Emollient; emulsifying agent. 
 
Applications in Pharmaceutical Formulation or Technology 
 Cholesterol is used in cosmetics and topical pharmaceutical formulations at 
concentrations of 0.3–5.0% w/w as an emulsifying agent. It imparts water-absorbing 
power to an ointment and has emollient activity. Cholesterol also has a physiological 
role. It is the major sterol of the higher animals, and it is found in all body tissues, 
especially in the brain and spinal cord. It is also the main constituent of gallstones. 
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Description 
 Cholesterol occurs as white or faintly yellow, almost odourless, pearly leaflets, 
needles, powder, or granules. On prolonged exposure to light and air, cholesterol 
acquires a yellow to tan colour. 
Solubility:     Chloroform1 in 4.5 
                       Acetone Soluble 
                       Ethanol (95%)    1 in 78 (slowly)  
                                                  1 in 3.6 at 80°C  
                       Ether                  1 in 2.8  
                       Methanol           1 in 294 at 0°C           
 
Stability and Storage Conditions 
 Cholesterol is stable and should be stored in a well-closed container, protected 
from light. 
Safety 
 Cholesterol is generally regarded as an essentially nontoxic and nonirritant 
material at the levels employed as an excipients. It has, however, exhibited 
experimental teratogenic and reproductive effects, and mutation data have been 
reported. Cholesterol is often derived from animal sources and this must be done in 
accordance with the regulations for human consumption. The risk of bovine 
spongiform encephalopathy (BSE) contamination has caused some concern over the 
use of animal-derived cholesterol in pharmaceutical products. However, synthetic 
methods of cholesterol manufacture have been developed (26) 
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                                     Objective of the study 
       Hydrocortisone is given by topical application for its anti-inflammatory effect in 
allergic rashes, eczema and certain other inflammatory conditions. 
       Hydrocortisone is synthetic carticosteriod and it is also a proved anti-
inflammatory drug. Hydrocortisone is available in different dosage forms for topical 
treatment. 
       Hydrocortisone is available with salt formations like hydrocortisone acetate, 
hydrocortisone butyrate,hydrocortisone sodium sucinate and other salt formations. 
      The available in market having trade names like  
1. CUTISOFT cream 1 % w/w         INNOVA (IPCA) 
2. ENTOFORM cream                     CIPLA  
3. HYDROCORT cream                 PFISCAR 
4. TENDRONE cream                   YASH PHARMA  
5. WYCORT ointment 2.5 %        WYETH        
     Hydrocortisone is found to have 10% absorption through topical route. It is also   
affected by pharmacokinetic parameters like plasma half life, plasma protein binding. 
To improve the   absorption of caroticosteroid thruough skin. Proniosome approach 
was tried using a less potent hydrocartisone. 
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¾ The objective of the study is to explore proniosomes for the delivery of     
hydrocortisone through transdermal route.  
¾ To enhance the transport / permeation of drug through skin without side 
effects. 
¾ To increase sustain pharmacodynamic activityof drug. 
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                                                 PLAN OF WORK 
 
1. Construction of Standard Curve 
2. Formulation of proniosome hydrocortisone gel in 1 % and 2.5 % by 
coacervation phase separation. 
3. Determination of Vesicle size by optical microscopy. 
4. Encapsulation efficiency by ultra centrifugation. 
5. Drug content uniformity. 
6. In-vitro drug release using sigma dialysis membrane. 
7. Ex In-vivo studies using rat skin. 
8. Anti inflammatory activity in mice Paw 
9. Drug Permeation study  in Human Skin by Prick test  
 
  
                                 58
 
                                         Materials and Methods 
 
 Hydrocortisone USP from SAMARTH LABS  
 Soya lecithin (phosphatidyl choline) from Hi-Media laboratories 
 Cholesterol from LOBA CHEMIE 
 Span 20,40,60,80 from LOBA CHEMIE 
 Tween 40, 60, 80 from LOBA CHEMIE 
 Dialysis Membrane was purchased from Hi-Media Laboratories (Mumbai, 
India).  
 Ethyl alcohol 99.9% 
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                                     Instruments 
 
 Magnetic stirrer 2MLH by REMI EQUIPMENTS 
 Rotary evaporator  
 Dialysis membrane 50 Himedia (Molecular weight cut-off ranges 12000 – 
14000) 
 UV spectrophotometer 1650 PC Shimadzu  
 Eppendroff Centrifuge 5415  
 pH Meter ELCO, LI 120  
 Electronic balance Shimadzu ELB 300  
 Eppendrop Tubes and other glass wares  
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Experimental Work 
Preparation of Standard Stock Solution 
 Accurately, weighed 10 mg of Hydrocortisone was dissolved in 5 ml of 
absolute alcohol to get a drug concentration (2 mg/ml). From this stock solution 1 ml 
solution was taken and transferred to 100 ml volumetric flask and made up the 
volume up to the mark with PBS pH 7.4 to obtain a standard stock solution of a drug 
concentration, 20 µg /ml.  
Selection of Analytical Wavelength for Hydrocortisone:   
           The λmax of Hydrocortisone is determined by appropriate dilution of the 
standard stock solution with PBS pH 7.4, the solution was scanned using the double 
beam UV visible spectrophotometer (Model: UV- 1650 PC, SHIMADZU) in the 
spectrum mode between the wavelength range of 400 nm to 200 nm. The λmax of 
Hydrocortisone is found to 248 nm as the wavelength for further analysis.  
     Figure 7:     Spectrum report for Hydrocortisone  
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     Table 1:        Wavelength of spectrum 
     
Standard Plot of Hydrocortisone: 
Standard stock solution was further diluted to get the different concentrations like 2, 
4, 6, 8, 10, 12, 14, 16, 18 and 20 µg/ml to determine the linearity range. Linearity was 
obtained in the above concentration at 248 nm using UV Spectrophotometer was 
shown in Table 1 & fig. 2.     
Table 2:       Standard Curve for Hydrocortisone 
S.No. Concentration of Drug  
            (µg / ml) 
Absorbance at 248nm  
1                  0       0 
2                  2       0.1749 
3                  4       0.289 
4                  6       0.424 
5                  8       0.555 
6                 10       0.726 
7                 12       0.854 
8                 14       1.000 
9                 16       1.116 
10                 18       1.273 
11                  20       1.414 
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 Figure 8: 
                                 Standard Graph for hydrocortisone 
      
 
Straight line equation Y = 0.06759 x   + 0.01742    
Correlation co-efficient r2 = 0.99917         
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Pre Formulation study: 
           Proniosomal gel was prepared by a coacervation-phase separation method 
.Precisely weighed amounts of surfactant, lecithin, cholesterol were taken in a clean 
and dry wide mouthed glass vial of 5.0 ml capacity and ethyl alcohol and water was 
added to it. After warming, all the ingredients were mixed well with a glass rod; the 
open end of the glass bottle was covered with a lid to prevent the loss of solvent from 
it and warmed over water bath at 60-70°C for about 5 min until the surfactant mixture 
was dissolved completely. Then the aqueous phase (0.1% glycerol solution) was 
added and warmed on a water bath till a clear solution was formed which was 
converted into Proniosomal gel on cooling (2).  
    Table 3:       
               Formulation using different ratios of Non ionic surfactant: 
S.No. Surfactant 
Type 
Ratio Soya lecithin 
(mg) 
Cholestero
l (mg) 
Ethanol 
(ml) 
Water 
(ml) 
 
1 
 
S20:S40 
 
  1:9 
  1:1 
  9:1 
 
100 
 
100 
 
2 
 
0.5 
 
2 
 
S20:S60 
 
  1:9 
  1:1 
  9:1 
 
100  
 
 
100 
 
2 
 
0.5 
 
3 
 
S20:S80 
 
  1:9 
  1:1 
  9:1 
 
100 
 
100 
 
2 
 
0.5 
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Formulation procedure: 
The proniosome hydrocortisone gel was prepared with 1 % and 2.5 % drug 
concentration with the same procedure described above using appropriate ratio of 
surfactants. The proniosome hydrocortisone gel formulation compositions are given in 
Table 4. (2) 
                  Table 4:   Composition of hydrocortisone gel formulation 
S.No. Formulation 
Type 
Drug  
conc. 
Surfactant 
Type 
Ratio Lecithin 
(mg) 
Cholesterol 
(mg) 
Ethanol 
(ml) 
Water
(ml) 
1 PHG 1 1% S20:S40 1:9 100 100 2 0.5 
2 PHG 2 1% S20:S60 1:9 100 100 2 0.5 
3 PHG 3 1% S20:S80 1:9 100 100 2 0.5 
4 PHG 4 1% S20:T40 1:9 100 100 2 0.5 
5 PHG 5 1% S20:T60 1:9 100 100 2 0.5 
6 PHG 6 1% S20:T80 1:9 100 100 2 0.5 
7 PHG 7 2.5% S20:S40 1:9 100 100 2 0.5 
8 PHG 8 2.5% S20:S60 1:9 100 100 2 0.5 
9 PHG 9 2.5% S20:S80 1:9 100 100 2 0.5 
10 PHG10 2.5% S20:T40 1:9 100 100 2 0.5 
11 PHG 11 2.5% S20:T60 1:9 100 100 2 0.5 
12 PHG 12 2.5% S20:T80 1:9 100 100 2 0.5 
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Characterization of Proniosomal Gel 
Vesicle Size Analysis:  
Proniosomal hydrocortisone gel (100 mg) was hydrated in saline solution (0.9% 
solution)   in a small glass vial with occasional shaking for 10 min. The dispersion 
was observed under optical microscope. The size of 50 vesicles was measured using a 
calibrated ocular and stage micrometer fitted in the optical microscope. Vesicle size is 
calculated using Equation 1. (2)  
          Number of divisions of stage micrometer 
 Size of each division = ------------------------------------------------------- X 10 Æ (1)  
                   Number of divisions of eye piece micrometer 
Table 5:    Vesicle Size Determination by Optical Microscope 
S.No Formulation Type Surfactant 
Type 
Drug 
conc. 
Vesicle size 
Range (µm)   
Average 
size (µm) 
1 PHG 1 S20:S40  1% 2 – 6  3 
2 PHG 2 S20:S60 1% 2 – 8    4 
3 PHG 3 S20:S80 1% 2 – 12   4.5 
4 PHG 4 S20:T40 1% 2 – 12  4 
5 PHG 5 S20:T60 1% 2 – 10   3.5 
6 PHG 6 S20:T80 1% 2 – 8    3 
7 PHG 7 S20:S40  2.5% 2 – 8  4 
8 PHG 8 S20:S60 2.5% 2 – 14  5 
9 PHG 9 S20:S80 2.5% 4 – 12  6 
10  PHG 10 S20:T40 2.5% 2 – 16  6.5 
11  PHG 11 S20:T60 2.5% 2 – 20 7 
12 PHG12 S20:T80 2.5% 4 – 10  6 
                                 66
 
Proniosome vesicle pictures for 12 different formulations are shown below.   
Figure 9                                                          Figure 10 
         PHG 1 (S20: 40 1%) in 40X                          PHG 2 (S20:60 1 %) in 40 X 
                                          
  
 Figure 11                                                             Figure 12 
          PHG 3 (S20:80 1%) in 40X                               PHG 3 (S20:80 1%) in 10X 
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    Figure 13                                                      Figure 14 
    PHG 4 (S20:T40 1 %) in 40X                     PHG 4 (S20:T40 1 %) in 10X 
                 
 
     Figure 15                                                     Figure 16 
       PHG 5 (S20:T60 1%) in 40x                         PHG 6 (S20:T80 1%) in 40X 
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   Figure 17                                                      Figure 18 
     PHG 7 (S20:40 2.5 %) in 40X                    PHG 8 (S20:60 2.5 %) in 40X 
            
 
 
 
  Figure 19                                                             Figure 20  
      PHG 9 (S20:80 2.5 %) in 40X                          PHG 10 (S20:T40 2.5 %) in 40X     
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Figure 21                                                            Figure 22 
      PHG 11 (S20:T60 2.5 %) in 40X                   PHG 12 (S20:T80 2.5 %) in 40X 
           
 
Encapsulation Efficiency:  
Encapsulation of hydrocortisone drug in Proniosomal gel was evaluated by dispersing 
the Proniosomal hydrocortisone gel (100 mg) in distilled water and the dispersion was 
warmed gently for the formation of niosomes. Then the dispersion was centrifuged at 
13000 rpm for 1hr at 50C. The supernatant was taken for the determination of free 
drug at 248 nm spectrophotometrically. (2)  
The percentage encapsulation efficiency was calculated from Equation 2. 
  % Encapsulation Efficiency = [(Ct - Cr)/Ct] X 100  Æ  (2)  
 Where,  
 Ct – Concentration of total Hydrocortisone. 
 Cr – Concentration of free drug in supernatant solution. 
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 Table 6:    Entrapment efficiency of Hydrocortisone 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              
Drug content uniformity: 
Formulated Proniosomal gel was mixed well and 100 mg of gel was weighed and 
transferred into vial. The gel was dissolved in 25 ml of phosphate buffer saline (pH 
7.4) with vigorous shaking, and the solutions were assayed for hydrocortisone content 
at 248 nm. Amount Drug content present in 100 mg gel was calculated by Equation 3. 
(27).  
 
 
 
S.No Surfactant Type % Entrapment 
1 PHG 1 (S20, S40 1%) 89.67% 
2 PHG 2 (S20, S60 1%) 79.66% 
3 PHG 3 (S20, S80 1%) 70.66% 
4 PHG 4 (S20, T40 1%) 58.88% 
5 PHG 5 (S20, T60 1%) 65.15% 
6 PHG 6 (S20, T80 1%) 27.20% 
7 PHG 7 (S20, S40 2.5%) 83.55% 
8 PHG 8 (S20, S60 2.5%) 80.00% 
9 PHG 9 (S20, S80 2.5%) 76.42% 
10 PHG 10(S20, T40 2.5%) 76.12% 
11 PHG 11(S20, T60 2.5%) 77.02% 
12 PHG 12(S20, T80 2.5%) 57.34% 
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Amount of drug = [(concentration) x (1) x (100) / 1000]  Æ (3)  
 
Table 7:   Drug content uniformity of proniosome hydrocortisone gel 
S.No. Formulation 
Type 
Surfactant  
Type 
Absorbance Concentration 
(mg) 
 
Amt. of 
Drug 
(25ml) 
% of 
drug 
1 PHG 1 S20, 40 (1 %) 3.9133 0.055984 1.399594 55.9837 
2 PHG 2 S20, 60 (1 % 3.91333 0.05598 1.399594 55.9837 
3 PHG 3 S20, 80 (1 %) 3.90134 0.055811 1.395287 55.8114 
4 PHG 4 S20, T40 (1 %) 3.91333 0.055984 1.399594 55.9837 
5 PHG 5 S20, T60 (1 %) 3.89917 0.05578 1.394507 55.7802 
6 PHG 6 S20, T80 (1 %) 3.91333 0.055984 1.399594 55.9837 
7 PHG 7 S20, 40 (2.5 %) 4.2137 0.0603 1.507501 24.3145 
8 PHG 8 S20, 60 (2.5 %) 4.00725 0.057333 1.433335 23.1183 
9 PHG 9 S20, 80 (2.5 %) 3.99988 0.057227 1.430687 23.0755 
10 PHG 10 S20,T40(2.5 %) 3.99481 0.057155 1.428865 23.0462 
11 PHG 11 S20,T60(2.5 %) 3.99988 0.057227 1.430687 23.0755 
12 PHG 12 S20,T80(2.5 %) 3.91333 0.055984 1.399594 22.5741 
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In vitro release studies:  
         Release from proniosome hydrocortisone gel was carried out using Himedia 
dialysis membranes 50 with the molecular weight cut-off range from 12000 - 14000. 
A weighed amount of (100 mg) Proniosomal gel formulation was dispersed in the 
dialysis membrane and the open ends of the membrane were covered with membrane 
closure clips. The membrane containing gel formulation was allowed to dip in 50 ml 
of receptor medium pH 7.4 phosphate buffer saline. The receptor medium was stirred 
using magnetic bead fitted to a magnetic stirrer at 60 rpm. Samples were withdrawn 
and replaced by equal volumes of fresh receptor medium at each sampling intervals to 
maintain sink condition. Samples withdrawn were analyzed by using 
spectrophotometer at 248 nm.  
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Table 8:  In-vitro Release for S20:40 1 % 
S.No TIME 
in min 
Absorbance Concentration 
(µg/ml) 
Concentration 
(mg) 
Amt. release   
50 ml 
Cumulative 
% release 
1 30 0.10266 1.224889 0.001225 0.061244 4.71111 
2 60 0.22437 2.973847 0.002974 0.148692 11.43787 
3 90 0.3417 4.659865 0.00466 0.232993 17.92256 
4 120 0.37063 5.075586 0.005076 0.253779 19.52148 
5 150 0.39651 5.447478 0.005447 0.272374 20.95184 
6 180 0.45712 6.318437 0.006318 0.315922 24.30168 
7 210 0.50566 7.015951 0.007016 0.350798 26.98443 
8 240 0.59443 8.291565 0.008292 0.414578 31.89063 
9 270 0.62297 8.701681 0.008702 0.435084 33.468 
10 300 0.68922 9.653686 0.009654 0.482684 37.12956 
11 330 0.70133 9.827705 0.009828 0.491385 37.79887 
12 360 0.77735 10.9201 0.01092 0.546005 42.0004 
13 420 0.78043 10.96436 0.010964 0.548218 42.17063 
14 480 0.66244 9.26886 0.009269 0.463443 35.64946 
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Table 9:   In-vitro Release for S20:60 1 % 
S.No TIME 
in min 
Absorbance Concentration 
(µg/ml) 
Concentration 
(mg) 
Amt. 
release   
50 ml 
Cumulative 
% release 
1 30 0.03979 0.321454 0.000321 0.016073 1.236362 
2 60 0.16846 2.170427 0.00217 0.108521 8.347795 
3 90 0.24219 3.229918 0.00323 0.161496 12.42276 
4 120 0.32214 4.37879 0.004379 0.21894 16.8415 
5 150 0.35669 4.875269 0.004875 0.243763 18.75104 
6 180 0.37268 5.105044 0.005105 0.255252 19.63478 
7 210 0.44147 6.093548 0.006094 0.304677 23.43672 
8 240 0.47771 6.614312 0.006614 0.330716 25.43966 
9 270 0.51907 7.208651 0.007209 0.360433 27.72558 
10 300 0.52664 7.317431 0.007317 0.365872 28.14396 
11 330 0.54043 7.515591 0.007516 0.37578 28.90612 
12 360 0.58508 8.157206 0.008157 0.40786 31.37387 
13 420 0.62047 8.665757 0.008666 0.433288 33.32983 
14 480 0.65182 9.116252 0.009116 0.455813 35.06251 
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Table 10:   In-vitro Release for S20:80 1 % 
S.No TIME 
in min 
Absorbance Concentration 
(µg/ml) 
Concentration 
(mg) 
Amt. 
release   
50 ml 
Cumulative % 
release 
1 30 0.10977 1.327058 0.001327 0.066353 5.104± (0.135) 
2 60 0.23584 3.138669 0.003139 0.156933 12.071± (0.563) 
3 90 0.34723 4.73933 0.004739 0.236967 18.228± (0.453) 
4 120 0.41711 5.743498 0.005743 0.287175 22.09± (1.453) 
5 150 0.44153 6.09441 0.006094 0.304721 23.440± (0.717) 
6 180 0.46606 6.446903 0.006447 0.322345 24.76 ± (1.313) 
7 210 0.53442 7.429228 0.007429 0.371461 28.573± (0.329) 
8 240 0.60013 8.373473 0.008373 0.418674 32.20 ± (0.190) 
9 270 0.69901 9.794367 0.009794 0.489718 37.670± (0.152) 
10 300 0.76355 10.7218 0.010722 0.53609 41.237± (0.77) 
11 330 0.82434 11.59534 0.011595 0.579767 44.59± (0.612) 
12 360 0.9013 12.70125 0.012701 0.635063 48.85 ± (0.136) 
13 420 0.95372 13.45452 0.013455 0.672726 51.748 ± (0.389)
14 480 1.07216 15.15649 0.015156 0.757824 58.294 ± (0.627)
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Table 11:    In-vitro Release for S20:T40 1 % 
S.No TIME 
in min 
Absorbance Concentration 
(µg/ml) 
Concentration 
(mg) 
Amt. 
release   
50v ml 
Cumulative 
% release 
1 30 0.06445 0.675815 0.000676 0.033791 2.448607 
2 60 0.4519 6.243426 0.006243 0.312171 22.62111 
3 90 0.52234 7.25564 0.007256 0.362782 26.28855 
4 120 0.5835 8.134502 0.008135 0.406725 29.47283 
5 150 0.62476 8.727403 0.008727 0.43637 31.62103 
6 180 0.62708 8.760741 0.008761 0.438037 31.74182 
7 210 0.63208 8.832591 0.008833 0.44163 32.00214 
8 240 0.64136 8.965943 0.008966 0.448297 32.4853 
9 270 0.68799 9.636011 0.009636 0.481801 34.91308 
10 300 0.69666 9.760598 0.009761 0.48803 35.36448 
11 330 0.72241 10.13062 0.010131 0.506531 36.70515 
12 360 0.75633 10.61805 0.010618 0.530902 38.47119 
13 420 0.78423 11.01897 0.011019 0.550948 39.9238 
14 480 0.84415 11.88001 0.01188 0.594001 43.04352 
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Table 12:   In-vitro Release for S20:T60 1 % 
S.No TIME 
in min 
Absorbance Concentration 
(µg/ml) 
Concentration 
(mg) 
Amt. 
release   
50 ml 
Cumulative 
% release 
1 30 0.09998 1.186377 0.001186 0.059319 4.329844 
2 60 0.42407 5.843512 0.005844 0.292176 21.32669 
3 90 0.55322 7.699382 0.007699 0.384969 28.09993 
4 120 0.67822 9.495617 0.009496 0.474781 34.65554 
5 150 0.73352 10.29027 0.01029 0.514514 37.55574 
6 180 0.74182 10.40954 0.01041 0.520477 37.99103 
7 210 0.74475 10.45165 0.010452 0.522582 38.14469 
8 240 0.7572 10.63055 0.010631 0.531528 38.79763 
9 270 0.79407 11.16037 0.01116 0.558018 40.73127 
10 300 0.82007 11.53398 0.011534 0.576699 42.09483 
11 330 0.82117 11.54979 0.01155 0.57749 42.15252 
12 360 0.8245 11.59764 0.011598 0.579882 42.32717 
13 420 0.82753 11.64118 0.011641 0.582059 42.48607 
14 480 0.83127 11.69493 0.011695 0.584746 42.68222 
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Table 13:   In-vitro Release for S20:T80 1 % 
S.No TIME 
in min 
Absorbance Concentration 
(µg/ml) 
Concentration 
(mg) 
Amt. 
release   
50 ml 
Cumulative 
% release 
1 30 0.07598 0.8415 0.000842 0.042075 3.048914 
2 60 0.32407 4.406524 0.004407 0.220326 15.96567 
3 90 0.45332 6.263831 0.006264 0.313192 22.69504 
4 120 0.57712 8.042822 0.008043 0.402141 29.14066 
5 150 0.63152 8.824544 0.008825 0.441227 31.97298 
6 180 0.69418 9.72496 0.009725 0.486248 35.23536 
7 210 0.72475 10.16425 0.010164 0.508212 36.82698 
8 240 0.75572 10.60928 0.010609 0.530464 38.43943 
9 270 0.78407 11.01667 0.011017 0.550833 39.91547 
10 300 0.782007 10.98702 0.010987 0.549351 39.80806 
11 330 0.83177 11.70211 0.011702 0.585106 42.39896 
12 360 0.83425 11.73775 0.011738 0.586887 42.52808 
13 420 0.83527 11.75241 0.011752 0.58762 42.58118 
14 480 0.82127 11.55123 0.011551 0.577561 41.85228 
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Table 14:    In-vitro Release for S20:40 2.5 % 
S.No TIME 
in min 
Absorbance Concentration 
(µg/ml) 
Concentration 
(mg) 
Amt. 
release   
50 ml 
Cumulative 
% release 
1 30 0.06812 0.728553 0.000729 0.036428 2.464658 
2 60 0.37146 5.087513 0.005088 0.254376 17.2108 
3 90 0.41748 5.748814 0.005749 0.287441 19.44795 
4 120 0.47278 6.543469 0.006543 0.327173 22.13623 
5 150 0.56909 7.927432 0.007927 0.396372 26.81811 
6 180 0.70898 9.937635 0.009938 0.496882 33.61852 
7 210 0.71558 10.03248 0.010032 0.501624 33.93936 
8 240 0.81384 11.44446 0.011444 0.572223 38.71604 
9 270 0.83484 11.74623 0.011746 0.587311 39.7369 
10 300 0.9198 12.96709 0.012967 0.648355 43.86703 
11 330 0.91772 12.9372 0.012937 0.64686 43.76591 
12 360 0.93054 13.12143 0.013121 0.656071 44.38913 
13 420 1.07031 15.1299 0.01513 0.756495 51.18371 
14 480 1.12439 15.90703 0.015907 0.795351 53.81268 
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Table 15:   In-vitro Release for S20:60 2.5 % 
S.No TIME 
in min 
Absorbance Concentration 
(µg/ml) 
Concentration 
(mg) 
Amt. 
release   
50 ml 
Cumulative 
% release 
1 30 0.09131 1.06179 0.001062 0.05309 3.604177 
2 60 0.39355 5.404943 0.005405 0.270247 18.34672 
3 90 0.48633 6.738181 0.006738 0.336909 22.8723 
4 120 0.55054 7.660871 0.007661 0.383044 26.00431 
5 150 0.59229 8.260813 0.008261 0.413041 28.04078 
6 180 0.5813 8.102888 0.008103 0.405144 27.50471 
7 210 0.59229 8.260813 0.008261 0.413041 28.04078 
8 240 0.72974 10.23595 0.010236 0.511798 34.74526 
9 270 0.84424 11.8813 0.011881 0.594065 40.33029 
10 300 0.85242 11.99885 0.011999 0.599943 40.7293 
11 330 0.94543 13.33539 0.013335 0.66677 45.2661 
12 360 1.07349 15.1756 0.015176 0.75878 51.51256 
13 420 0.95447 13.4653 0.013465 0.673265 45.70705 
14 480 0.8551 12.03736 0.012037 0.601868 40.86002 
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Table 16:   In-vitro Release for S20:80 2.5 % 
S.No TIME 
in min 
Absorbance Concentration 
(µg/ml) 
Concentration 
(mg) 
Amt. 
release   
50 ml 
Cumulative 
% release 
1 30 0.05258 0.505245 0.000505 0.025262 1.766591 
2 60 0.16797 2.163386 0.002163 0.108169 7.564285 
3 90 0.27319 3.675384 0.003675 0.183769 12.85099 
4 120 0.30664 4.156057 0.004156 0.207803 14.53167 
5 150 0.34985 4.776979 0.004777 0.238849 16.70273 
6 180 0.38867 5.334818 0.005335 0.266741 18.65321 
7 210 0.45972 6.355798 0.006356 0.31779 22.22307 
8 240 0.48877 6.773243 0.006773 0.338662 23.68267 
9 270 0.51465 7.145136 0.007145 0.357257 24.98299 
10 300 0.52112 7.238109 0.007238 0.361905 25.30807 
11 330 0.5249 7.292427 0.007292 0.364621 25.498 
12 360 0.52844 7.343296 0.007343 0.367165 25.67586 
13 420 0.53362 7.417732 0.007418 0.370887 25.93613 
14 480 0.59563 8.308809 0.008309 0.41544 29.05178 
 
 
 
 
 
                                 82
 
 
Table 17: In-vitro Release for S20:T40 2.5 % 
S.No TIME 
in min 
Absorbance Concentration 
(µg/ml) 
Concentration 
(mg) 
Amt. 
release   
50 ml 
Cumulative 
% release 
1 30 0.09778 1.154764 0.001155 0.057738 4.037635 
2 60 0.41675 5.738324 0.005738 0.286916 20.06407 
3 90 0.63184 8.829142 0.008829 0.441457 30.87113 
4 120 0.63184 8.829142 0.008829 0.441457 30.87113 
5 150 0.76648 10.7639 0.010764 0.538195 37.63602 
6 180 0.86035 12.1128 0.012113 0.60564 42.35246 
7 210 0.92505 13.04253 0.013043 0.652127 45.60327 
8 240 0.96753 13.65297 0.013653 0.682648 47.73765 
9 300 1.1145 15.76491 0.015765 0.788245 55.12206 
10 360 1.15198 16.30349 0.016303 0.815175 57.00522 
11 420 1.13733 16.09297 0.016093 0.804649 56.26914 
12 480 1.10632 15.64736 0.015647 0.782368 54.71106 
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Table 18:    In-vitro release for S20:T60 2.5 % 
S.No TIME 
in min 
Absorbance Concentration 
(µg/ml) 
Concentration 
(mg) 
Amt. 
release   
50 ml 
Cumulative 
% release 
1 30 0.0387 0.305791 0.000306 0.01529 1.0692 
2 60 0.18958 2.473919 0.002474 0.123696 8.650065 
3 90 0.25867 3.466734 0.003467 0.173337 12.12145 
4 120 0.36536 4.999856 0.005 0.249993 17.48202 
5 150 0.40076 5.50855 0.005509 0.275428 19.26066 
6 180 0.43848 6.050582 0.006051 0.302529 21.15588 
7 210 0.47278 6.543469 0.006543 0.327173 22.87926 
8 240 0.49939 6.925851 0.006926 0.346293 24.21626 
9 300 0.51819 7.196005 0.007196 0.3598 25.16086 
10 360 0.59155 8.25018 0.00825 0.412509 28.84678 
11 420 0.62183 8.6853 0.008685 0.434265 30.36818 
12 480 0.63918 8.934617 0.008935 0.446731 31.23992 
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Table 19:   In-vitro Release for S20:T80 2.5 % 
S.No TIME 
in min 
Absorbance Concentration 
(µg/ml) 
Concentration 
(mg) 
Amt. 
release   
50 ml 
Cumulative 
% release 
1 30 0.04968 0.463572 0.000464 0.023179 1.67961 
2 60 0.39453 5.419026 0.005419 0.270951 19.63415 
3 90 0.48633 6.738181 0.006738 0.336909 24.4137 
4 120 0.55054 7.660871 0.007661 0.383044 27.75678 
5 150 0.6283 8.778273 0.008778 0.438914 31.80534 
6 180 0.69861 9.788619 0.009789 0.489431 35.46601 
7 210 0.75134 10.54634 0.010546 0.527317 38.21139 
8 240 0.75867 10.65167 0.010652 0.532584 38.59302 
9 300 0.77502 10.88662 0.010887 0.544331 39.44428 
10 360 0.81006 11.39014 0.01139 0.569507 41.26863 
11 420 0.81421 11.44978 0.01145 0.572489 41.4847 
12 480 0.81531 11.46558 0.011466 0.573279 41.54197 
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Table 20:  In-vitro Release for marketed 1 % Hydrocortisone cream  
S.No TIME 
in min 
Absorbance Concentration 
(µg/ml) 
Concentration 
(mg) 
Amt. 
release   
50 ml 
Cumulative 
% release 
1 30 0.05273 0.5074 0.000507 0.02537 2.537002 
2 60 0.53845 7.487139 0.007487 0.374357 37.43569 
3 90 0.53308 7.409973 0.00741 0.370499 37.04986 
4 120 0.5332 7.411697 0.007412 0.370585 37.05849 
5 150 0.49219 6.822388 0.006822 0.341119 34.11194 
6 180 0.44702 6.173301 0.006173 0.308665 30.8665 
7 210 0.46899 6.489007 0.006489 0.32445 32.44504 
8 240 0.33618 4.580543 0.004581 0.229027 22.90272 
9 300 0.31897 4.333238 0.004333 0.216662 21.66619 
10 360 0.29272 3.956028 0.003956 0.197801 19.78014 
11 420 0.36462 4.989223 0.004989 0.249461 24.94611 
12 480 0.34656 4.729703 0.00473 0.236485 23.64851 
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Table 21:  
Release comparison of 1 % PHG preparations & Marketed Hydrocortisone 1 % 
Cumulative % release  of 1 % proniosome formulation S.No
. 
Time 
in 
min 
S20:S40 S20:S60 S20:S80 S20:T40 S20:T60 S20:T80 
Hydrocort
isone 
CREAM 
1% 
1 30 4.71111 1.23636 5.10407 2.44860 4.32984 3.04891 2.537002 
2 60 11.4379 8.34779 12.0718 22.6211 21.3266 15.9656 37.43569 
3 90 17.9226 12.4227 18.2281 26.2885 28.0999 22.6950 37.04986 
4 120 19.5215 16.8415 22.0903 29.4728 34.6555 29.1406 37.05849 
5 150 20.9518 18.7510 23.4400 31.6210 37.5557 31.9729 34.11194 
6 180 24.3017 19.6347 24.7957 31.7418 37.9910 35.2353 30.8665 
7 210 26.9844 23.4367 28.5739 32.0021 38.1446 36.8269 32.44504 
8 240 31.8906 25.4396 32.2056 32.4853 38.7976 38.4394 22.90272 
9 270 33.468 27.7255 37.6706 34.9130 40.7312 39.9154 21.66619 
10 300 37.1296 28.1439 41.2376 35.3644 42.0948 39.8080 19.78014 
11 330 37.7989 28.9061 44.5974 36.7051 42.1525 42.3989 24.94611 
12 360 42.0004 31.3738 48.8509 38.4711 42.3271 42.5280 23.64851 
13 420 42.1706 33.3298 51.7481 39.9238 42.4860 42.5811 _____ 
14 480 35.6495 35.0625 58.2941 43.0435 42.6822 41.8522 _____ 
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  Figure23: 
Release of 1 % PHG Formulation  comparing with 
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Table 22:  Release comparison of 2.5 % PHG preparations  
Cumulative % release of 1 % proniosome formulations S.No Time in 
mins 
 
S20:S40 S20:S60 S20:S80 S20:T40 S20:T60 S20:T80 
1 30 2.464658 3.604177 1.766591 4.037635 1.0692 1.67961 
2 60 17.2108 18.34672 7.564285 20.06407 8.650065 19.63415
3 90 19.44795 22.8723 12.85099 30.87113 12.12145 24.4137 
4 120 22.13623 26.00431 14.53167 30.87113 17.48202 27.75678
5 150 26.81811 28.04078 16.70273 37.63602 19.26066 31.80534
6 180 33.61852 27.50471 18.65321 42.35246 21.15588 35.46601
7 210 33.93936 28.04078 22.22307 45.60327 22.87926 38.21139
8 240 38.71604 34.74526 23.68267 47.73765 24.21626 38.59302
9 300 43.86703 40.7293 25.30807 55.12206 25.16086 39.44428
10 360 44.38913 51.51256 25.67586 57.00522 28.84678 41.26863
11 420 51.18371 45.70705 25.93613 56.26914 30.36818 41.4847 
12 480 53.81268 40.86002 29.05178 54.71106 31.23992 41.54197
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Figure 24: 
 %  release 2.5 % proniosome fromulations 
0
10
20
30
40
50
60
0 30 60 90 120 150 180 210 240 300 360 420
Time in min
Cu
m
ul
at
iv
e 
%
 r
el
ea
se
S20:S40
S20:S60
S20:S80
S20:T40
S20:T60
S20:T80
 
 
  Kinetics for S20: 80 1 % PHG formulation:  
Figure 25: 
Zero order reaction of S20:80 1% PHG formulation
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   Regression coefficient    r2    =   0.998334541  
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Figure 26: 
First order reaction of S20: 80 1 % PHG 
formulation
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              Regression coefficient    r2   =    0.9631 
  
 
Figure 27: 
        Higuchi plot of S20: 80 1 % PHG Formulation
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   Regression coefficient    r2   =     0.998953     
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Figure 28: 
          PEPPAS plot of S20: 80 1% PHG formulation
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   Regression coefficient    r2   = 0.994415 
                                      Slope = 0.893036  
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Ex In-vivo studies:   
          Institutional animal ethics committee (PSG institute of medical sciences and 
research) has grant approval for animal usage Reg No: 158 / 1999 / CPCSEA on 5th 
January, 2009. 
 
          The permeation of Proniosomal hydrocortisone gel was determined by Franz 
(vertical) diffusion cell using excised Rat skin as membrane mounted on the receptor 
compartment with the stratum corneum side facing upwards into the donor 
compartment. A weighed amount of proniosome hydrocortisone gel was applied on 
the stratum corneum facing upwards in to the donor compartment. The receptor 
compartment was filled with pH 7.4 phosphate buffer saline 15 ml medium to 
maintain a sink condition. Sampling was regularly done at predetermined time. The 
available diffusion area of the cell was 1.5 cm2. The receptor medium was stirred by a 
magnetic bead. Samples withdrawn were analyzed using spectrophotometer at 248 
nm. (2) (1). 
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Table 23:    
Release comparison of 1 % PHG formulations using diffusion cell in rat skin  
Cumulative % release of 1 % proniosome formulations S.No. TIME 
in 
MINS 
S20:40 S20:60 S20:80 S20:T40 S20:T60 S20:T80 
1 30 0.327633 0.063457 0.382986 0.107913 0.480116 0.194063
2 60 0.799167 0.196063 0.544992 0.32732 0.977059 0.506851
3 90 0.734416 0.419974 1.151976 0.358749 1.175676 0.402032
4 120 0.755971 0.711137 1.304584 0.398208 1.323362 0.570925
5 150 0.866504 0.913062 1.675758 0.543355 1.304275 0.278961
6 180 0.972812 1.072137 2.051329 0.543355 1.368349 0.455085
7 210 1.101193 1.747837 1.956747 0.557331 1.260123 0.30653 
8 240 1.586693 2.054864 1.801293 0.58577 1.185863 0.253478
9 270 2.895675 2.045725 1.805087 0.663854 1.407808 0.267071
10 300 3.634488 1.81414 1.722144 1.217256 1.467223 0.199174
11 330 3.934445 2.404052 1.585314 1.161666 1.291099 0.130824
12 360 4.576692 2.70901 1.722144 1.112855 1.123041 0.107913
13 420 6.197356 3.185199 3.420319 1.667544 2.093634 0.197053
14 480 6.696738 3.29168 4.524788 1.639105 2.589951 0.114275
15 540 7.093174 3.70467 5.336887 1.690454 2.923911 0.068454
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Figure29: 
1% PHG FORMULATION RELEASE IN DIFFUSION CELL
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Table 24:     
Release comparison of 2.5 % PHG formulations using diffusion cell in rat skin 
Cumulative % release of proniosome formulations S.No. TIME 
in 
MINS 
S20:40 S20:60 S20:80 S20:T40 S20:T60 S20:T80 
1 30 0.399195 0.264521 0.461273 0.409229 0.482654 0.338376
2 60 1.13387 0.932806 2.114787 0.431305 0.710961 0.5493 
3 90 1.339072 1.254835 2.527346 0.481368 1.095889 0.741103
4 120 1.450639 1.721109 2.988274 0.277258 1.105658 0.816232
5 150 1.462193 1.825348 2.823078 0.270443 1.125614 0.842967
6 180 1.482196 1.152752 3.349274 0.171987 1.154886 0.842967
7 210 1.612732 1.165426 2.709441 0.171569 1.176094 0.919765
8 240 1.716885 1.314844 2.696767 0.156307 1.334417 1.099296
9 270 1.970542 1.459089 2.544159 0.271313 1.373459 1.092934
10 300 2.12634 1.321138 3.467222 0.330693 1.478313 1.159962
11 330 1.90217 1.158011 3.434545 0.407803 1.577952 1.152349
12 360 1.826383 1.04334 3.693462 0.470834 1.582541 1.216804
13 420 2.564162 0.999023 4.009455 0.649043 1.713886 1.299999
14 480 3.467395 0.915994 4.696537 0.83 2.012629 1.43875 
15 540 5.571921 0.886507 5.129013 0.543008 2.11651 1.366645
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Figure 30:   
2.5% PHG FORMULATION RELEASE IN DIFUSSION 
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Statistical analysis: 
Comparison between the invitro and invivo results in S20:80 1 % proniosome 
hydrocortisone gel formulation was performed by analysis of variance (one way 
ANOVA with turkeys multiple camparision post test) with graph pad prism (version 
3.0) software. 
Anti inflammatory action: 
Acute and chronic inflammation models were used to evaluate the anti-inflammatory 
activity, the study was carried out after the approval of animal ethical committee. 
Weighed mice range from 35 -49 g were used. In acute model carrageenan were used 
to induce inflammation in mice hind paw.  0.1ml of 1% carrageenan in normal saline 
was injected in to mice paw. In this three groups of animals were used. (18).  
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    Figure 31:  Injecting carrageenan to induce inflammation in mice paw   
                          
 
Table 25:   Animal Group Type 
S.No Group Type No. of  Animals 
1 I 1 mice 
2 II 3 mice 
3 III 3 mice 
 
Group I is used as control (0.1ml 1% carrageenan in normal saline). Group II received 
the marketed hydrocortisone cream 1% (100 mg). Group III received the proniosome 
hydrocortisone gel 1% (100 mg). The Anti inflammatory effect of marketed and 
Proniosomal formulations were determined by Screw gauge. The paw volume was 
measured initially and then at 1, 2, 3 and 4hr after the carrageenan injection.   
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Table 26:      Comparative Anti-inflammatory activity in Mice   
S.No. Group 
Type 
Animals 
in group 
Paw size before 
inflammation(mm)
0 
hr(mm)
1hr 
(mm)
2hr 
(mm) 
3hr 
(mm) 
4hr 
(mm)
1 I 1 2.65 3.5 4.7 5.0 5.1 4.0 
2 II 1 3.05 3.90 3.64 3.6 3.45 3.4 
3  2 2.75 3.55 3.67 3.46 3.3 3.25 
4  3 2.80 3.60 3.38 3.2 3.1 3.1 
5 III 1 3.25 4 3.72 3.29 3.1 3.05 
6  2 2.90 3.75 3.84 3.6 3.05 2.8 
7  3 2.64 3.49 3.55 3.28 3.09 2.75 
 
Drug permeation testing in human volunteers:  
Prick test: Anti inflammatory activity were evaluated in human volunteers using 
skin prick test. It was done for Control, Marketed formulation and Proniosomal 
formulation.  
                   Skin prick testing is most commonly performed on the forearm. The 
pronisome hydrocortisone gel 1% and hydrocortisone cream 1% marketed 
formulation was applied twice a day in occlusion conditions at marked area. After 24 
hr. occlusion dressing was removed and the arm was cleaned, then a drop of 
commercially-produced allergen (histamine) is placed onto a marked area of skin. 
Using a sterile lancet, a small prick through the drop is made. This allows a small 
amount of allergen to enter the skin.   
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           The histamine wheal suppression was measured using scale. The ability of 
histamine wheal suppression of proniosome hydrocortisone gel 1% was compared 
with marketed hydrocortisone cream 1% and control. (26) 
 
Table 27:      Histamine Wheal Size using prick test in Human Volunteers 
Histamine wheal size S.No. Formulation Type 
 Sample I 
(mm) 
Sample II 
(mm) 
Sample III 
(mm) 
Average 
mean (mm) 
1 Control 
 
4 5 4 4.6 
2 Marketed 
hydrocortisone 1% 
4.5 6 4.5 5 
3 PHG (S20:80 1 %) 
 
4 6 5 5 
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RESULTS AND DISCUSSION: 
 
Hydrocortisone is a synthetic corticosteroid drug which may be given by injection or 
by topical application. It is given by topical application for its anti-inflammatory 
effect in allergic rashes, eczema and certain other inflammatory conditions. 
Hydrocortisone is available in creams, lotions for topical application but it is affected 
by number of pharmacokinetic parameters like drug absorption ,plasma half life 
,plasma protein binding.(22) 
Standard curve:  
             Spectrum of hydrocortisone was determined by double beam UV visible 
spectrophotometer in the spectrum mode range from 400 nm to 200nm with 
appropriate dilution of standard stock solution. 
             Standard plot for hydrocortisone was carried out in spectrophotometry at 248 
nm by different concentrations of stock solution like 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 
µg/ml.    
Pre formulaton: 
             Proniosomes a novel drug delivery system for topical application was 
investigated in this study. Proniosome hydrocortisone gel formulations with non ionic 
surfactants combination were prepared by coacervation-phase separation method after 
optimizing the non-ionic surfactant ratio for vesicle formation in different 
combination of surfactants in Table 4.(2)  
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Formulation: 
            After Pre formulation studies non-ionic surfactant ratio 1:9 shows better 
vesicle formation than the 1:1and 9:1. Hence Proniosome Hydrocortisone gel with 
different non ionic surfactants in 1:9 ratio containing 1% and 2.5% Hydrocortisone 
with Soya lecithin was formulated. 
Determination of vesicle size:  
            Vesicle size of proniosome hydrocortisone gel formulations was determined 
using optical microscope. Vesicle formation was good in S20:80 1 % (PHG 3) 
combination showed in (fig.11) and poor in S20: T80 2.5 % (PHG) combination 
showed in fig. 22. (2). 
            Vesicle formation and size was good in S20:80 (fig 11) and poor in S20:T80 
(fig 16) in 1 % PHG formulations. 
            Vesicle formation and size was good in S20: 40 (fig 17) and poor in S20:T80 
(fig 22) when comparing in 2.5 % PHG formulations. 
            Vesicles obtained from Span combination formulations was found in the size 
range 3 – 6 µm and Span, Tween combination formulations  4 – 7 µm. 
Encapsulation efficiency: 
           Encapsulation of Proniosomal hydrocortisone gel prepared using different 
surfactant combinations was determined by ultra centrifugation.   
           The percentage entrapment of hydrocortisone gel varies from 27 – 89 %. 
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           Entrapment was high in S20: 40 (89.67 %) and poor in S20:T80 (27.2 %) in 1 
% proniosome hydrocortisone gel. And in 2.5 % proniosome hydrocortisone gel 
entrapment was found high in S20:40 (83.55 %) and poor in S20: T80 (57.34 %). This 
shows the entrapment of S20:40 are high and S20: T80 are poor in both 1 % and 2.5 
% formulations (Table 6).  
          Among the 12 PHG formulations entrapment efficiency was high in S20:40 1 % 
(89.67 %) and poor in S20:T80 1 % (27.20 %). (Table 6). 
         High entrapment in Span combinations may be due to hydrophobic nature of 
surfactants and drug. (2). (5) 
Drug content uniformity: 
            Drug content of proniosome hydrocortisone gel was calculated (equation 3) 
and percentage drug content each formulation was given in Table 7. 
            Drug content of proniosome hydrocortisone gel shows 1 % PHG formulations 
having uniform distribution than in 2.5 % PHG formulations, but drug concentration 
is more in 2.5 % PHG formulations. 
In Vitro release: 
             Drug release from proniosome gel was determined using dialysis membrane.  
Proniosome hydrocortisone gel formulation was compared with marketed 1 % 
hydrocortisone cream. The initial hour release from marketed formulation was found 
to be high when compared with PHG 1 %. But the cumulative percent release from 1 
% hydrocortisone cream was not proper and linear with respect to time when 
compared to 1 % PHG formulation.  
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           Maximum 34.7 % of drug was found to be release from marketed 1 % cream 
through dialysis membrane in 2 hr. where as 58 % of drug was found to be release 
from (S20: 80 1 %) PHG formulation showed extend release up to 8 hr. Cumulative 
release comparison for 1 % PHG formulation with marketed 1 % hydrocortisone 
cream was given in Table 21 and fig 23. 
           The cumulative release from 2.5 % PHG formulation shows sustained release 
similarly as 1 % PHG. But here good release was shown from S20:40 (53.81 %) and 
poor from S20: 80 (29.05 %). Table 22 and fig. 24 
           In 1 % PHG formulation S20: 80 (58.29%) shows good release and S20: 60 
(35.06 %) shows poor release. Comparative release was shown in table 21 and fig. 23 
           Cumulative release in Span combinations S20:80 1 % (58.29 %) shows high 
and   S20: 80 2.5 % (29.05 %) was poor. And from Span, Tween combinations S20: 
T40 2.5 % was high and S20: T60 2.5 % (31.23 %) was poor.  
         In vitro results show S20:80 combinations with 1 % drug concentration 58.29 ± 
0.626 having good release than other formulations. 
 Release Kinetics: 
           Release kinetic parameters of proniosome hydrocortisone gel 1 % (S20:80) 
was carried out using zero order, first order, Higuchi and Peppas kinetics.  
             Regression value of PHG 1 % (S20:80) was 0.99833 for zero order and 
0.9631 in first order. Results show the formulation obeys mixed order kinetics.   
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         The Higuchi plot value for proniosome hydrocortisone gel 1 % (S20:80) was 
more than 0.998. Hence it follows diffusion release mechanism. The slope value of 
Peppas plot was 0.8930 which confirms non fickian diffusion type shown in fig. 25, 
26, 27, and 28.  
Ex in vivo studies: 
              Ex invivo release study was carried out in vertical Franz diffusion cell. The 
releases from all the formulations were found to be low through rat skin. But it shows 
linearity in release with respect to time. 
              The cumulative percent release of 1 % PHG formulations through rat skin 
was given in Table 23 and fig 29. 
              The cumulative percent release of 2.5 % PHG formulations through rat skin 
is given in Table 24 and fig 30. This shows S20: 40 1 % (7.09 %) is high and S20: 
T80 2.5 % is poor. (1). (5)   
             The lower amount of drug release through rat skin may be due to lower 
adsorption and fusion of proniosome onto surface of skin and the lipid bilayers of 
proniosomes does not show rate-limiting membrane barrier in this study. 
Anti inflammatory action:     
           Anti inflammatory action of proniosome hydrocortisone gel 1% PHG 3 (S20: 
80 1 %) was compared with the marketed topical 1% hydrocortisone cream 
formulation and control in mice. Measurements of inflammated mice paw before 
treatment and after treatment with respect to time intervals up to 4 hr. Table 6.   
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           Anti inflammatory study results shows, the marketed formulation was good in 
initial hours later the activity got reduces their. But in proniosome hydrocortisone gel 
formulation the activity was less in initial hours but later it shows promising anti   
inflammatory action than in marketed after 4 hr.  
          When comparing with control, marketed 1 % hydrocortisone and proniosome 
hydrocortisone gel 1 % (S20: 80) for anti inflammatory activity significance was P < 
0.001. When comparing with marketed hydrocortisone 1 % and proniosome 
hydrocortisone gel 1 % (S20: 80) the significance was P < 0.05.  
DRUG PERMEATION STUDIES IN HUMAN VOLUNTEERS: 
Skin prick test:  
            The formulation which has showing promising results in invivo study was 
taken for prick test in human volunteers. 
            Drug permeation and anti-inflammatory action of PHG 3 (S20:80 1 %) 
formulation was carried out in human volunteers. To check the drug permeability and 
histamine wheal suppression activity skin test was carried out in 3 volunteers as a 
mock trail. Comparison between marketed hydrocortisone cream 1 % with PHG (S20: 
80 1 %) formulation and alcohol as control was carried out. The wheal suppression 
was high with alcohol followed by proniosome formulation when compared with 
marketed formulation. (26)  
            This study can extend in more no. of volunteers after getting clearance from 
human ethical committee and after incorporating penetration enhancers in the 
formation.  
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Conclusion: 
 
             The proniosome hydrocortisone gel 1% and 2.5% was prepared by using 
various surfactant combinations by coacervation phase separation method. The in 
vitro permeation of different formulations containing mixture of non-ionic surfactants 
have been studied and evaluated. The cumulative release from (S20: 80 1 %) PHG 
was 58.92 ± 0.627.  
             Proniosome hydrocortisone gel shows diffusion release type which was 
confirmed by Higuchi and Peppas plot.  Comparison of Proniosome formulation with 
marketed 1 % hydrocortisone cream, proniosome formulation shows better 
cumulative release and anti inflammatory activity than in marketed formulation. 
Phospholipids and non-ionic surfactants in an optimum ratio in the Proniosomes may 
act as penetration enhancers, which are useful for increasing the permeation of 
hydrocortisone through skin. 
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